BR112017000865A2 - comprimidos de rucaparibe de concentração de dosagem alta - Google Patents

comprimidos de rucaparibe de concentração de dosagem alta

Info

Publication number
BR112017000865A2
BR112017000865A2 BR112017000865A BR112017000865A BR112017000865A2 BR 112017000865 A2 BR112017000865 A2 BR 112017000865A2 BR 112017000865 A BR112017000865 A BR 112017000865A BR 112017000865 A BR112017000865 A BR 112017000865A BR 112017000865 A2 BR112017000865 A2 BR 112017000865A2
Authority
BR
Brazil
Prior art keywords
rucaparib
tablets
high dosage
tablet
cansilate
Prior art date
Application number
BR112017000865A
Other languages
English (en)
Inventor
Etter Jeffrey
Original Assignee
Clovis Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clovis Oncology Inc filed Critical Clovis Oncology Inc
Publication of BR112017000865A2 publication Critical patent/BR112017000865A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

divulgou-se um comprimido incluindo alta dosagem de sal de cansilato de 8-flúor-2-(4-[(metilamino)metil]fenil)-1,3,4,5-tetra-hidro-6h-azepino[5,4,3-cd]indol-6-ona. a invenção é dirigida aos comprimidos de rucaparibe de concentração de dosagem alta. em algumas modalidades, o comprimido inclui 45-90% p/p de cansilato de rucaparibe. em algumas modalidades, o comprimido granulado seco inclui 45-90% p/p de cansilato de rucaparibe. tal modalidade é um comprimido contendo pelo menos 200 mg de rucaparibe. outra modalidade é um comprimido contendo pelo menos 300 mg de rucaparibe.
BR112017000865A 2014-08-22 2015-08-17 comprimidos de rucaparibe de concentração de dosagem alta BR112017000865A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462040849P 2014-08-22 2014-08-22
US201562101739P 2015-01-09 2015-01-09
PCT/US2015/045522 WO2016028689A1 (en) 2014-08-22 2015-08-17 High dosage strength tablets of rucaparib

Publications (1)

Publication Number Publication Date
BR112017000865A2 true BR112017000865A2 (pt) 2017-12-05

Family

ID=55347324

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017000865A BR112017000865A2 (pt) 2014-08-22 2015-08-17 comprimidos de rucaparibe de concentração de dosagem alta

Country Status (14)

Country Link
US (3) US9987285B2 (pt)
EP (1) EP3182975A4 (pt)
JP (3) JP6574477B2 (pt)
KR (2) KR20230097211A (pt)
CN (2) CN113209033A (pt)
AU (2) AU2015305696B2 (pt)
BR (1) BR112017000865A2 (pt)
CA (1) CA2955495C (pt)
IL (1) IL249946B (pt)
MX (1) MX367260B (pt)
NZ (1) NZ728392A (pt)
RU (1) RU2705156C2 (pt)
SG (1) SG11201700265VA (pt)
WO (1) WO2016028689A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2019123406A (ru) 2014-02-05 2019-10-03 Мерк Шарп И Доум Корп. Технология приготовления таблеток для cgrp-активных соединений
KR20230097211A (ko) * 2014-08-22 2023-06-30 클로비스 온콜로지 인코포레이티드 루카파립의 고 용량 강도 정제
CN106008530B (zh) * 2016-07-24 2018-06-26 石家庄久正生物科技有限公司 一种抗卵巢癌药物Rucaparib关键中间体的制备方法
CN108201534A (zh) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种瑞卡帕布口服缓控释药物组合物及其用途
WO2018140377A1 (en) 2017-01-24 2018-08-02 Assia Chemical Industries Ltd. Solid state forms of rucaparib and of rucaparib salts
CA3058375A1 (en) 2017-03-27 2018-10-04 Tesaro, Inc. Niraparib compositions
MX2020003760A (es) * 2017-09-26 2020-07-29 Tesaro Inc Formulaciones de niraparib.
WO2019130229A1 (en) 2017-12-28 2019-07-04 Mylan Laboratories Ltd Methods and intermediates for preparing rucaparib
TWI820077B (zh) 2018-01-05 2023-11-01 美商斯布雷克薩一號公司 治療涉及酸性或缺氧性患病組織之疾病之化合物、組合物及方法
CN109111454A (zh) * 2018-08-01 2019-01-01 宁波金未生物科技有限公司 一种瑞卡帕布s-樟脑磺酸盐
CN108853030B (zh) * 2018-09-26 2021-10-01 上海朝晖药业有限公司 一种治疗恶性肿瘤的药物制剂及其制备方法
CN111542527A (zh) * 2018-12-06 2020-08-14 上海诚妙医药科技有限公司 芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途
EP3996749A1 (en) 2019-07-10 2022-05-18 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics
US11634508B2 (en) 2019-07-10 2023-04-25 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
WO2021220120A1 (en) 2020-04-28 2021-11-04 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
EP4182318A1 (en) 2020-07-14 2023-05-24 Assia Chemical Industries Ltd Solid state forms of rucaparib salts
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
WO2022215034A1 (en) 2021-04-08 2022-10-13 Rhizen Pharmaceuticals Ag Inhibitors of poly(adp-ribose) polymerase
US11738029B2 (en) * 2021-11-10 2023-08-29 Crititech, Inc. Rucaparib particles and uses thereof
WO2023137060A1 (en) 2022-01-11 2023-07-20 Assia Chemical Industries Ltd. Solid state forms of rucaparib tosylate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100632079B1 (ko) 1999-01-11 2006-10-04 아구론 파마슈티컬스, 인크. 폴리(ａｄｐ-리보오스) 중합 효소의 트리사이클릭 저해제
WO2004087713A1 (en) 2003-03-31 2004-10-14 Pfizer Inc. Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
US7351701B2 (en) 2003-07-25 2008-04-01 Cancer Research Technology Limited Therapeutic compounds
CA2581200A1 (en) 2004-09-22 2006-03-30 Pfizer Inc. Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor
EP1794163B1 (en) 2004-09-22 2009-12-23 Pfizer, Inc. Method of preparing poly(adp-ribose) polymerases inhibitors
BRPI0516766A (pt) 2004-09-22 2008-09-16 Pfizer formas polimórficas e amorfas do sal de fosfato de 8-flúor-2{4-[(metilamino)metil]fenil}-1,3,4,5-tetraidro- 6h-azepino[5,4,3-cd]indol-6-ona, composição farmacêutica, formas de dosagens e respectivo uso
US20110136883A1 (en) * 2008-04-09 2011-06-09 Lek Pharmaceuticals D.D. Granulation of active pharmaceutical ingredients
WO2011098971A1 (en) * 2010-02-12 2011-08-18 Pfizer Inc. Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
CA2869309C (en) 2012-04-05 2021-02-09 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase and combination therapies thereof
KR20230097211A (ko) 2014-08-22 2023-06-30 클로비스 온콜로지 인코포레이티드 루카파립의 고 용량 강도 정제

Also Published As

Publication number Publication date
NZ728392A (en) 2023-06-30
JP2017525712A (ja) 2017-09-07
AU2015305696A1 (en) 2017-02-02
MX367260B (es) 2019-08-12
US20190099430A1 (en) 2019-04-04
AU2015305696B2 (en) 2019-08-29
US20180200260A1 (en) 2018-07-19
AU2019272064B2 (en) 2021-11-18
AU2019272064A1 (en) 2019-12-19
MX2017001540A (es) 2017-05-11
RU2017109139A3 (pt) 2019-03-06
JP2020002149A (ja) 2020-01-09
KR20230097211A (ko) 2023-06-30
CN113209033A (zh) 2021-08-06
JP7127101B2 (ja) 2022-08-29
SG11201700265VA (en) 2017-02-27
KR20170043597A (ko) 2017-04-21
JP6797980B2 (ja) 2020-12-09
IL249946A0 (en) 2017-03-30
US20160051561A1 (en) 2016-02-25
CN106794185A (zh) 2017-05-31
CA2955495A1 (en) 2016-02-25
CA2955495C (en) 2023-09-19
EP3182975A4 (en) 2018-04-18
RU2017109139A (ru) 2018-09-24
US10130636B2 (en) 2018-11-20
US9987285B2 (en) 2018-06-05
WO2016028689A1 (en) 2016-02-25
EP3182975A1 (en) 2017-06-28
JP2021038242A (ja) 2021-03-11
JP6574477B2 (ja) 2019-09-11
IL249946B (en) 2020-05-31
RU2705156C2 (ru) 2019-11-05

Similar Documents

Publication Publication Date Title
BR112017000865A2 (pt) comprimidos de rucaparibe de concentração de dosagem alta
CL2013002063A1 (es) Compuestos derivados de pirrolo(piridina, pirimidina o pirazina), inhibidores de serina/trionina cinasa; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer, infecciones inflamaciones y enfermedades autoinmune.
CL2016000952A1 (es) Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2016002310A1 (es) Nuevos compuestos bicíclicos.
GT201600123A (es) Inhibidores de syk
BR112016001678A2 (pt) Composição, método de fabricação de um comprimido, comprimido, forma de dosagem unitária, artigo de fabricação, e, uso de uma composição, de um comprimido ou de uma forma de dosagem unitária
MX2019001125A (es) Inhibidores de cinasa macrociclica.
CL2016001131A1 (es) Uso de una combinación farmacéutica que comprende un compuesto inhibidor de mdm2 y uno o más agentes activos adicionales para el tratamiento del cáncer y composiciones farmacéuticas que comprenden dichas combinaciones.
CO2017002160A2 (es) Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
CL2018001199A1 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
CL2016001266A1 (es) Nuevo octahidro-ciclobuta[1,2-c;3,4-c']dipirrol-2-ilo.
CL2017002456A1 (es) Composiciones y métodos para el tratamiento de la anemia.
BR112016013502A2 (pt) unidade de dosagem sólida que desintegra oralmente contendo um componente de estetrol.
CL2015002060A1 (es) Compuestos.
CL2015002897A1 (es) Inhibidores de bace1
CO2019012571A2 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton
CL2017000682A1 (es) Compuestos novedosos de imidazopiridazina y su uso.
JP2015190819A5 (pt)
AR112471A1 (es) Antagonistas del receptor del factor liberador de corticotropina
EA201591456A1 (ru) Макроциклические и бициклические ингибиторы вируса гепатита с
BR112017024719A2 (pt) compostos de hidroxil purina e seu uso
BR112015023078A2 (pt) inibidores de pirrolopirimindina cdk9 quinase
CL2015003014A1 (es) Composición farmacéutica que comprende 0,5-5 mg de (11?,17?)-17-hidroxi-11-[4-(metilsulfonil)fenil]-17-(pentafluoroetil)estra-4,9-dien-3-ona; forma de dosificación oral; uso para tratar y/o prevenir una enfermedad ginecológica, tal como, fibroides en el útero, endometriosis o hemorragias menstruales excesivas.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]